5th Anti-Infectives Partnering & Deal-Making Summit
We invite you to join your business development and infectious disease colleagues to discuss new collaborative advancements in infectious disease R&D including anti-virals, anti-fungals, emerging pathogens and new technologies at GTCbio’s 5th annual Anti-Infectives Partnering & Deal-Making Summit (http://www.gtcbio.com/conferenceDetails.aspx?id=117) taking place on March 6-7, 2008 in Philadelphia, PA.
This very specialized summit takes a microscopic look at trends and developments in infectious diseases, from cutting-edge anti-infective research to early and late stage partnerships. Whether you are a business development professional or a infectious disease specialist, this conference will help you grasp a full scope of the market for new treatments and therapies for all types of infectious diseases.
Hear from keynote presenter Dr. John Shiver, Vice President, Worldwide Basic Research Franchise Head, Vaccines, Merck & Co. on “A Vaccine Renaissance: New Vaccines for the World.” Also take part of our special panel discussion on: “Investment Opportunities in the Anti-Infectives Space” featuring key leaders in venture capitalism.
Topics include:
- Current Models of R&D Collaboration
+ Human Genome Sciences Collaboration with Novartis for Development and Commercialization of Albuferon(TM)
+ Biota-Boehringer Ingelheim: Making the Right Deal: It’s Not Just About the Money
+ Replenishing the GSK Infectious Disease R&D Pipeline Using Innovative Deals Structures with Strategic Collaborators
- New Pathogen Challenges
+ Multi-Resistant Pseudomonas and Acinetobacter - Challenges and Perspectives
+ Genetic Determinants of Tetracycline Resistance and their Occurrence in Escherichia Coli Isolates from the Pivotal Tigecycline Phase 3 Clinical Trials
+ Your ‘Plan B’ When All Else Fails? Another Alternative for Your Anti-Infective Compounds
- Future of Infectious Disease Therapeutics
+ Clinical Trial Design & Regulatory Approval
+ Positioning Antibacterials within the Hospital and Community Markets amid Regulatory Changes and Continuing Uncertainty
+ Combination Therapy / Dual Mechanism Agents
- New Technologies in Anti-Infectives
+ Hepatitis B Vaccine: Hepislav
+ Oritavancin, a Potent Lipo-Glycopeptide with Unusual Pharmacokinetic Properties that may Allow Single or Infrequent Dosing Schedules
Register today to reserve your spot! Team Registration: Register 2, the 3rd goes free! For more information call 626-256-6405 or visit www.gtcbio.com.
PRESENTERS
David Apelian, Chief Medical Officer, GlobeImmune
James Chafouleas, Director, Global Licensing, Virology, Boehringer Ingelheim
Mark Coflin, Global Executive Director, Infectious Disease Alliance Management, Novartis
Danielle Drayton, Senior Analyst, Decision Resources
Michael Dudley, Vice President of Drug Development, Mpex Pharmaceuticals
Jacques Dumas, Associate Director, Infection Chemistry, AstraZeneca R&D
Roger M. Echols, Chief Medical Officer, Replidyne, Inc.
Leigh Farrell, Vice President, Business Development, Biota
Margery B. Fischbein, Human Genome Science
Lisa Gray, Phoenix IP Ventures
Jennifer Hartt, Ben Franklin Technology Partners of Southeastern PA
Hal Jones, Infectious Disease Research, Wyeth Research
Damien McDevitt, Director, Business Development, Infectious Diseases, GlaxoSmithKline
Eric Meltzer, Curtis Financial Group
Dennis Molnar, Vice President, Corporate Development, Paratek Pharmaceuticals
Douglas Pon, Assist. Vice President, Vaccine Licensing Global Business Development, Wyeth
Malcolm Page, Head, Discovery Biology, Basilea Pharmaceuticals
Gary Patou, MPM Capital
Glenn Tillotson, Ph.D., Executive Director of Scientific Affairs, Replidyne, Inc.
Michael S. Ostrach, Chief Business Officer, Dynavax Technologies Corporation
Gerald Siuta, Head of Business Development, Global Alliance for TB Drug Development
Paul Stewart, Manager, Global Business Development, Eli Lilly and Co.
Daniel Sikkema, Merck & Co.
